World health day 2011: antimicrobial resistance and practical solutions

Annals of the Academy of Medicine Singapore

Volumn 40, Issue 4, 2011, Pages 156-157

  Lye, David Cb ^a   Kwa, Andrea Lh ^b   Chlebicki, Piotr ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIVIRAL RESISTANCE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; ESCHERICHIA COLI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRESCRIPTION; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SINGAPORE; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 79957442623     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Editorial

References (15)

1. TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010;36 S3:S8-14.
2. Raviglione MC, Smith IM. XDR tuberculosis--implications for global public health. N Engl J Med 2007;356:656-9.
3. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin Infect Dis 2005;41Suppl 4:S239-46.
4. Guerin PJ, Bates SJ, Sibley CH. Global resistance surveillance: ensuring antimalarial effi cacy in the future. Curr Opin Infect Dis 2009;22:593-600.
5. Hsu LY, Tan TY, Jureen R, Koh TH, Krishnan P, Lin RT, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis 2007;13:1944-7.
6. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. Version 14. Melbourne: Therapeutic Guidelines Limited, 2010.
7. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77.
8. Young J, De Sutter A, Merenstein D, van Essen GA, Kaiser L, Varonen H, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet 2008;371:908-14.
9. Smucny J, Fahey T, Becker L, Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2004;4:CD000245.
10. Sirinavin S, Garner P. Antibiotics for treating salmonella gut infections. Cochrane Database Syst Rev 2000;2:CD001167.
11. Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005;4:CD003543.
12. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37:497-507.
13. N Singh, P Rogers, CW Atwood, MM Wagener, VL Yu. Short-course empiric antibiotic therapy for patients with pulmonary infi ltrates in the intensive care unit. Am J Respir Crit Care Med 2000;162:505-11.
14. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al; PneumA Trial Group. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-98.
15. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.